Real World Evidence
BEXSERO has a foundation of evidence data, which you may consider when vaccinating against meningococcal serogroup B disease (MenB). This data can help you better understand how BEXSERO can help protect patients in the real world - and not just in the setting of a clinical trial.
BEXSERO has shown an impact following a mass vaccination campaign against MenB disease in a region of Canada 1
In the Saguenay-Lac-Saint-Jean region of Quebec, Canada, 83% of population 2 months to 20 years (~59,500 individuals) was immunized at least with one dose with Bexsero in 2014 in response to a MenB outbreak. 1
In the four years following the vaccination campaign, serogroup B incidence fell by 96% from 11.4 to 0.4/100,000 between the periods of 2006-14 to 2014-18. 1 The four years following the vaccination compaign, serogroup B incidence fell by 96% from 11.4/100.000 in 2006-14 to 0.4/100.000 in 2014-18 (p<0.0001).
MenB cases per 100,000
Reduction in MenB incidence during the BEXSERO vaccination program in Saguenay-Lac-St-Jean (Quebec, Canada). From 2014-2018 an estimated 83% of 59,000 residents aged 2 months to 20 years of age received at least 1 dose of Bexsero. 1